Atara Biotherapeutics
ATRA
140 hedge funds and large institutions have $1.07B invested in Atara Biotherapeutics in 2020 Q3 according to their latest regulatory filings, with 33 funds opening new positions, 52 increasing their positions, 37 reducing their positions, and 14 closing their positions.
136% more first-time investments, than exits
New positions opened: 33 | Existing positions closed: 14
126% more call options, than puts
Call options by funds: $1.76M | Put options by funds: $778K
41% more repeat investments, than reductions
Existing positions increased: 52 | Existing positions reduced: 37
15% more funds holding
Funds holding: 122 → 140 (+18)
0.1% more ownership
Funds ownership: 4.34% → 4.44% (+0.1%)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
5% less capital invested
Capital invested by funds: $1.13B → $1.07B (-$61.7M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
+$29.7M |
| 2 |
JP Morgan Chase
New York
|
+$19.4M |
| 3 |
BlackRock
New York
|
+$10.4M |
| 4 |
Morgan Stanley
New York
|
+$7.25M |
| 5 |
IC
Ikarian Capital
Dallas,
Texas
|
+$5.81M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$11.3M |
| 2 |
CCM
Consonance Capital Management
New York
|
-$7.53M |
| 3 |
Marshall Wace
London,
United Kingdom
|
-$6.77M |
| 4 |
SPC
Slate Path Capital
New York
|
-$6.12M |
| 5 |
Goldman Sachs
New York
|
-$4.92M |
ATRA Hedge Fund Activity: Q3 2020 in Review
140 of the 4,970 institutional investors tracked by Wall St. Rank reported a position in Atara Biotherapeutics (ATRA) for Q3 2020, worth a combined $1.07B — down 5.5% from $1.13B a quarter earlier.
Buyers outnumbered sellers: 33 funds opened new ATRA positions and 14 closed out — a net gain of 19 holders — while 52 added to existing stakes and 37 trimmed.
The largest buyer was Wasatch Advisors, adding an estimated $29.7M. The largest seller was Assenagon Asset Management, exiting entirely with an estimated $11.3M sold.
- 140 institutional investors held Atara Biotherapeutics (ATRA) as of Q3 2020, up from 122 in Q2 2020.
- Funds reported $1.07B of Atara Biotherapeutics stock for Q3 2020, down 5.5% quarter-over-quarter.
- 33 funds opened new Atara Biotherapeutics positions in Q3 2020 and 14 closed out, a net change of +19 holders.
- The largest Atara Biotherapeutics buyer in Q3 2020 was Wasatch Advisors, an estimated $29.7M added.
- The largest Atara Biotherapeutics seller in Q3 2020 was Assenagon Asset Management, an estimated $11.3M sold.
Based on aggregated 13F filings for Q3 2020.